News

MRSA Raises Tx Failure Rates Of Diabetic Foot Infections


 

SAN FRANCISCO — The isolation of methicillin-resistant Staphylococcus aureus, either alone or as part of a polymicrobial infection, was associated with treatment failure in 35% of patients with a diabetic foot infection, Dr. Matthew E. Falagas noted in a poster session at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy.

The finding comes from an analysis of 15 randomized, controlled trials that compared the use of different antibiotics for treating diabetic foot infections.

The analysis showed “a considerable proportion of patients with diabetes who have infection in their foot would not be treated effectively with current [antimicrobial] management,” Dr. Falagas of the Alfa Institute of Biomedical Sciences in Athens, Greece, said in an interview. “About one-fourth of patients fail to be cured with the current antimicrobial regimens and treatment.”

He and his associates found that different regimens of appropriate antibiotics (including penicillins, carbapenems, cephalosporins, and fluoroquinolones) were associated with similar treatment failures. But in the 68 patients whose infections were caused by methicillin-resistant Staphylococcus aureus (MRSA) alone or as part of a polymicrobial infection, treatment failure was 35%, compared with 23% in the 1,522 patients whose infections were caused by different bacteria.

In patients with infections caused by MRSA, the use of linezolid was not associated with a significantly lower failure rate, compared with other antibiotics (32% vs. 37%, respectively). The researchers also observed no significant differences in overall treatment failure when they compared patients who had osteomyelitis with those who did not (27% vs. 23%, respectively).

The treatment failures seen in the study were not a matter of patient compliance “because most of these patients were treated in the hospital with [intravenous] antimicrobial agents,” said Dr. Falagas, who is also with the department of medicine at Tufts University, Boston. Patients who took carbapenems had fewer treatment failures, he added.

Treatment failure occurred in 35% of patients with an MRSA infection. Courtesy Dr. Matthew E. Falagas

Recommended Reading

Telephone Outreach Boosts Pneumococcal Shot Rates
MDedge Family Medicine
AOM Trails 30% of Upper Respiratory Infections
MDedge Family Medicine
Dose Amoxicillin For Otitis Media By Vaccine Hx
MDedge Family Medicine
Combo Vaccine Shaves Little Off the Bottom Line
MDedge Family Medicine
Pneumococcal Immunization Coverage Has Jumped to 80%
MDedge Family Medicine
Low-Dose, Whole-Virion Vaccine For Avian Flu Looks Promising
MDedge Family Medicine
Nonsusceptible Pneumococci Up in Replacement Serotypes
MDedge Family Medicine
Identify Risk Factors to Guide Pneumonia Therapy
MDedge Family Medicine
Adacel Shortage Should Resolve by 2007
MDedge Family Medicine
FDA Panel Rejects Gemifloxacin for Sinusitis
MDedge Family Medicine